

Abbott India Limited  
3-4, Corporate Park,  
Sion Trombay Road,  
Mumbai 400 071, India

Tel : (91-22) 6797 8888  
Fax : (91-22) 6797 8920  
E-mail : webmaster@abbott.co.in  
Site : www.abbott.co.in



**By Fax/ Hand**

Bombay Stock Exchange Limited  
Corporate Relations Department  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 001

August 11, 2011

**Scrip Code: 500488**

Dear Sirs:

**Unaudited Financial Results for the Quarter ended June 30, 2011**

We vide our letter dated August 11, 2011 submitted the unaudited Financial Results for the quarter ended June 30, 2011.

We would like to bring to your notice that following typographical errors have occurred in the same:

1. Item number 2(f) other expenditure, figures of half year ended June 30, 2011 (in the third column) comma is placed incorrectly i.e. 14,884 should be read as 148,84
2. In the Notes – Note number 3(a) last line should be read as : These shares are pending allotment and have been disclosed as "Share Capital - Pending Allotment" under the "Unaudited Statement of Assets and Liabilities" under note 6 below. (Note number was erroneously mentioned as 5 instead of 6)

The results, duly corrected with the above changes are attached for your records. Kindly make the necessary changes on the website.

Thank you.

Kindly acknowledge receipt.

Thank you

Yours faithfully  
Abbott India Limited

  
Krupa Anandpara  
Company Secretary

Abbott India Limited  
3-4, Corporate Park,  
Sion Trombay Road,  
Mumbai 400 071, India

Tel : (91-22) 6797 8888  
Fax : (91-22) 6797 8920  
E-mail : webmaster@abbott.co.in  
Site : www.abbott.co.in



**By Fax/ Hand**

Bombay Stock Exchange Limited  
Corporate Relations Department  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 001

August 11, 2011

**Scrip Code: 500488**

Dear Sirs:

**Unaudited Financial Results for the Quarter ended June 30, 2011**

We vide our letter dated August 11, 2011 submitted the unaudited Financial Results for the quarter ended June 30, 2011.

We would like to bring to your notice that following typographical errors have occurred in the same:

1. Item number 2(f) other expenditure, figures of half year ended June 30, 2011 (in the third column) comma is placed incorrectly i.e. 14,884 should be read as 148,84
2. In the Notes – Note number 3(a) last line should be read as : These shares are pending allotment and have been disclosed as "Share Capital - Pending Allotment" under the "Unaudited Statement of Assets and Liabilities" under note 6 below. (Note number was erroneously mentioned as 5 instead of 6)

The results, duly corrected with the above changes are attached for your records. Kindly make the necessary changes on the website.

Thank you.

Kindly acknowledge receipt.

Thank you

Yours faithfully  
Abbott India Limited

  
Krupa Anandpara  
Company Secretary

Abbott India Limited  
3-4, Corporate Park,  
Sion Trombay Road,  
Mumbai 400 071, India

Tel : (91-22) 6797 8888  
Fax : (91-22) 6797 8920  
E-mail : webmaster@abbott.co.in  
Site : www.abbott.co.in



Unaudited Financial Results for the quarter and six months ended June 30, 2011

Rs. in Lakhs

Sr No	Particulars	3 Months ended		6 Months ended		Previous Period from December 1, 2009 to December 31, 2010 Audited
		June 30, 2011	May 31, 2010	June 30, 2011	May 31, 2010	
		Unaudited	Unaudited	Unaudited	Unaudited	
1	Net Sales/ Income from Operations					
	(a) Gross Sales	355,88	224,37	672,91	426,43	995,98
	Less : Excise Duty	4,46	1,37	7,83	2,60	6,10
	Net Sales	351,42	223,00	665,08	423,83	989,88
	(b) Other Operating Income	7,00	5,62	15,60	10,87	29,07
2	Expenditure					
	(a) (Increase)/ Decrease in Stock In Trade & Work in Progress	(6,14)	11,29	(10,54)	12,37	(25,08)
	(b) Consumption of Raw Materials	32,14	8,72	61,50	16,74	44,19
	(c) Purchase of Traded Goods	180,43	126,88	341,97	251,77	628,20
	(d) Employees Cost	43,83	24,95	81,86	46,54	112,94
	(e) Depreciation/ Amortisation	3,21	2,24	6,48	4,26	11,25
	(f) Other Expenditure	82,08	34,71	148,84	65,86	160,19
	(g) Total Expenditure	335,55	208,79	630,11	397,54	931,69
3	Profit from Operations before other Income and Interest (1-2)	22,87	19,83	50,57	37,16	87,26
4	Other Income	5,31	1,16	9,00	2,22	6,93
5	Profit Before Interest (3+4)	28,18	20,99	59,57	39,38	94,19
6	Interest	-	-	2	1	4
7	Profit Before Tax	28,18	20,99	59,55	39,37	94,15
8	Tax Expense (including current tax, deferred tax and prior period adjustments for the period)	11,08	6,92	19,67	13,50	33,21
9	Net Profit for the period	17,10	14,07	39,88	25,87	60,94
10	Paid-up Equity Share Capital (Refer note 3) (Face Value of the share - Rs 10/-)	13,68	13,68	13,68	13,68	13,68
11	Reserves excluding revaluation reserves (as per last audited Balance Sheet)					291,71
12	Earnings Per Share (EPS) (Refer note 3)					
	Basic EPS for the periods (not annualised), year to date (not annualised) and for the previous period - Rs.	12.50	10.29	29.16	18.92	44.56
	Diluted EPS for the periods (not annualised), year to date (not annualised) and for the previous period - Rs.	8.05	10.29	18.77	18.92	44.56
13	Public shareholding					
	Number of Shares	44,71,056	42,47,056	44,71,056	42,47,056	42,47,056
	Percentage of Shareholding	32.69%	31.06%	32.69%	31.06%	31.06%
14	Promoters and promoter group shareholding					
	(a) Pledged/ Encumbered :					
	Number of Shares	-	-	-	-	-
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-
	Percentage of Shares (as a % of the total share capital of the company)	-	-	-	-	-
	(b) Non - encumbered :					
	Number of Shares	92,04,184	94,28,184	92,04,184	94,28,184	94,28,184
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%
	Percentage of Shares (as a % of the total share capital of the company)	67.31%	68.94%	67.31%	68.94%	68.94%

**Notes :**

1. The results for the quarter and six months ended June 30, 2011 have been reviewed by the Audit Committee, approved by the Board of Directors and subjected to a "Limited Review" by the auditors of the Company, in compliance with Clause 41 of the Listing Agreement with Bombay Stock Exchange Limited.
2. The Company changed its accounting year from year ended November 30 to year ended December 31 from previous financial year onwards. Accordingly, the results for the current quarter and six months are for the period ending June 30, 2011 and the corresponding previous quarter and six months are for the period ending May 31, 2010.
3. a) The Scheme of Amalgamation ('the Scheme') of Solvay Pharma India Limited (hereinafter referred to as "Solvay Pharma") with the Company was sanctioned by the Hon'ble High Court of Bombay vide its Order dated July 15, 2011. A copy of the said Order was filed with the Registrar of Companies on August 10, 2011 (effective date). The swap ratio for the merger is 2:3 i.e. every two shares of Solvay Pharma will entitle their holder to three shares of the Company. These shares are pending allotment and have been disclosed as "Share Capital - Pending Allotment" under the "Unaudited Statement of Assets and Liabilities" under note 6 below.  
 (b) In terms of the Scheme, the amalgamation shall take place effective January 1, 2011 ('The Appointed Date'). The Scheme has accordingly been given effect to in these financial statements. The Unaudited Statement of Assets and Liabilities includes the assets, liabilities and reserves of Solvay Pharma with effect from the Appointed Date and the results for the current quarter and six months ended June 30, 2011 includes the results of Solvay Pharma.  
 (c) The amalgamation has been accounted for under the "pooling of interests" method as prescribed by Accounting Standard 14 (AS 14) "Accounting for Amalgamations". Accordingly, the assets, liabilities and reserves of the erstwhile Solvay Pharma as at December 31, 2010 have been taken over at their book values after  
 (i) Financial effect of any conflicting accounting policies between the Company and Solvay Pharma has been adjusted against the opening assets, liabilities and reserves.  
 (ii) The additional share capital to be allotted by the Company over the amount of share capital of Solvay Pharma has been adjusted in reserves.  
 (d) As on June 30, 2011, assets, liabilities and arrangements remain in the name of Solvay Pharma pending completion of certain formalities of transfer pursuant to the Scheme mentioned above.  
 (e) Solvay Pharma was engaged in the business of manufacturing and trading of pharmaceutical products and the primary segment for classification of business activities is "Pharmaceuticals".  
 (f) After the allotment of share capital to the shareholders of Solvay Pharma in terms of the Scheme of Amalgamation, the paid up share capital of the company, public shareholding and promoters and promoter group shareholding would be as follows :

Sr No	Particulars	No of Equity shares of Rs. 10/- each	Rs. in Lakhs
1	Total shareholding : Paid-up Equity Share Capital Number of Shares		21,25
2	Public shareholding : Paid-up Equity Share Capital Number of Shares	2,12,49,799	5,32
	Percentage of Shareholding	53,15,751 25.02%	
3	Promoters and promoter group shareholding : Paid-up Equity Share Capital Number of Shares Percentage of Shareholding	1,59,34,048 74.98%	15,93

After allotment of share capital to the shareholders of Solvay Pharma, the Basic/ Diluted Earnings per Share for the current quarter and six months ended June 30, 2011 would be Rs. 8.05 and Rs. 18.77 respectively.

4. In view of the change of accounting year referred in note 2 and the amalgamation referred in note 3, the results for the quarter and six months ended June 30, 2011 are not comparable to those of the corresponding previous periods. The results for the current quarter & half year ended June 30, 2011 are for Abbott India Limited post merger of Solvay Pharma. The results for the corresponding previous quarter, half year and for 13 months period ended December 31, 2010 are for Abbott India Limited only.
5. The Company continues to make significant strategic investments for expanding its field force to improve market coverage. The Company also continues to increase advertisement & promotional efforts to capture market share and increase brand equity & patient /customer awareness. These initiatives are impacting the near term profitability. Further, the Other Expenses for the current period under review also includes integration, amalgamation expenses and stamp duty
6. Unaudited Statement of Assets and Liabilities :

Particulars	Rs. in Lakhs	
	As at June 30, 2011 Unaudited	As at May 31, 2010 Unaudited
Shareholders Funds		
(a) Capital	13,68	13,68
(b) Share Capital - Pending Allotment (refer note 3(a) above)	7,57	-
(c) Reserves	484,39	283,75
Deferred Tax Liability (Net)	-	1,30
<b>Total</b>	<b>505,64</b>	<b>298,73</b>
Fixed Assets	79,78	50,53
Deferred Tax Asset (Net)	4,08	-
Current Assets, Loans and Advances		
(a) Inventories	165,76	91,28
(b) Sundry Debtors	78,48	48,29
(c) Cash and Bank Balances	290,64	182,37
(d) Other Current Assets	3,27	64
(e) Loans and Advances	35,65	10,32
	<b>573,80</b>	<b>332,90</b>
Less : Current Liabilities and Provisions		
(a) Liabilities	(136,16)	(65,88)
(b) Provisions	(15,86)	(18,82)
	<b>(152,02)</b>	<b>(84,70)</b>
Net Current Assets	<b>421,78</b>	<b>248,20</b>
<b>Total</b>	<b>505,64</b>	<b>298,73</b>

7. As approved by the members of the Company at their Annual General Meeting held on April 27, 2011, the company has paid dividend of Rs. 17.00 per share on 1,36,75,240 equity shares of Rs 10.00 each for the period December 1, 2009 to December 31, 2010, amounting to Rs 27,11 Lakhs (including Corporate Dividend Tax). Further as approved by the members of erstwhile Solvay Pharma at their Annual General Meeting held on April 18, 2011, the company has paid dividend of Rs. 25.50 per share on 50,49,706 equity shares of Rs 10.00 each for the year ended December 31, 2010, amounting to Rs 15,02 Lakhs (including Corporate Dividend Tax).
8. The Company operates in one reportable business segment i.e. "Pharmaceuticals" and one reportable geographical segment i.e. "Within India".

9. There was 1 investor complaint pending at the beginning of the quarter. The Company received 8 complaints from the investors, 8 complaints have been resolved and disposed off during the quarter. There was 1 complaint lying unresolved at the end of the quarter.
10. Figures for the prior period have been regrouped and/or reclassified wherever considered necessary.

Mumbai:  
Date: August 11, 2011

For and on behalf of the Board,



Vivek Mohan  
Managing Director